For Immediate Release
Chicago, IL – April 15, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Abbott Laboratories (
ABT Quick Quote ABT - Free Report) , salesforce.com, inc. ( CRM Quick Quote CRM - Free Report) , BHP Group ( BHP Quick Quote BHP - Free Report) , Danaher Corporation ( DHR Quick Quote DHR - Free Report) and Zoom Video Communications, Inc. ( ZM Quick Quote ZM - Free Report) . Here are highlights from Wednesday’s Analyst Blog: Top Stock Reports for Abbott, salesforce and BHP
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Abbott, salesforce.com, and BHP Group. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today's research reports here >>>
Abbott have outperformed the Zacks Medical Products industry over the past year (+34% vs. +20.6%). The Zacks analyst believes that the branded generics and international diabetes businesses should drive growth in the coming quarters. New product launches and acquisitions are likely to boost sales further.
The company has been seeing improvements in testing and procedure volumes across its hospital-based businesses. At the same time, its consumer-facing businesses like diabetes care, nutrition and established pharmaceuticals (EPD), are catching up pace.
Diabetes Care sales were strong on solid worldwide adoption of FreeStyle Libre in the fourth quarter of 2020. In 2020, the company received U.S. approval of Freestyle Libre 2 and CE Mark for Libre 3 and Libre Sense Glucose Sport. Yet, the company's performance was disappointing particularly in Pediatric Nutrition, Cardiovascular and Neuromodulation.
) read the full research report on Abbott here >>> salesforce shares have lost -10.6% over the last six months against the Zacks Computer Software industry's gain of +13.4%. The Zacks analyst believes that the company is benefiting from a robust demand environment as customers are undergoing a major digital transformation.
The rapid adoption of its cloud-based solutions is driving demand for its products. Continued deal wins in the international market is another growth driver. Furthermore, the recent deal to acquire Slack would position the company to be a leader in the enterprise team collaboration solution space and better compete with Microsoft's Teams product.
However, stiff competition remains a concern. Besides, unfavorable currency fluctuations along with increasing investments in international expansions and data centers are an overhang on near-term profitability.
) read the full research report on salesforce here >>>
BHP Group have gained +3% in the past three months against the Zacks Mining - Miscellaneous industry's gain of +13.1%. The Zacks analyst believes that the company's efforts to make operations more efficient through smart technology adoption across the entire value chain will continue to aid in reducing costs, thereby boosting margins.
BHP Group expects to produce 245-255 Mt (million tons) of iron ore in fiscal 2021. Iron ore prices have been gaining on the back of strong demand in China and supply concerns, which will reflect on the company's results.
It plans to simplify its coal portfolio and concentrate on higher quality coking coals to capitalize on demand from steelmakers. The company has four major projects under development in petroleum, iron ore and potash, which are likely to drive growth in the long run.
) read the full research report on BHP Group here >>>
Other noteworthy reports we are featuring today include Danaher and Zoom Video.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.